Latest Advances in Lung Cancer Research

Patients with ROS1 lung cancer have a new option. On July 22, 2026, the FDA approved zidesamtinib, sold as Jideytro. The maker is Nuvalent, Inc.

Discover why 9 in 10 lung cancer patients miss out on clinical trial discussions and how asking one key question early can unlock life-saving options.

Large trial finds nivolumab after lung cancer surgery didn’t improve survival or prevent recurrence compared to observation alone.

New drug ivonescimab cut death risk 34% in lung cancer trial, outperforming standard immunotherapy plus chemo combination.

Selpercatinib cut lung cancer recurrence risk by 83% in patients with rare RET-positive early-stage non-small cell lung cancer.

New data shows elisrasib provides strong, lasting tumor responses for advanced lung cancer patients, including those who failed previous KRAS-targeted treatments.

New pill sevabertinib (Hyrnuo) shrinks tumors in 70% of patients with rare HER2-mutated lung cancer. Learn about this FDA fast-tracked breakthrough.

A new Phase 3 trial finds Ivonescimab paired with chemotherapy delayed lung cancer progression by 40 % compared to a PD-1 inhibitor combo.

FDA fast-tracks ZL-1310, a promising targeted therapy showing 74% response rate in advanced small cell lung cancer patients with limited treatment options.

AbbVie’s Emrelis, an FDA-approved drug, targets c-Met proteins in NSCLC for effective cancer treatment, marking significant advancements in antibody-drug conjugates (ADCs).

Phase III trial shows mobocertinib performs similarly to chemotherapy for EGFR exon 20 insertion lung cancer patients.